Latest Hemophilia news
ASH: Sustained Benefit Seen for Etranacogene Dezaparvovec in Hemophilia B
posted December 10th
by modernClinician Editorial Team
by modernClinician Editorial Team
Efanesoctocog Alfa Not Cost-Effective for Prophylaxis in Hemophilia A
posted April 28th
by modernClinician Editorial Team
by modernClinician Editorial Team
FDA Approves Qfitlia to Cut Bleeding Episodes in Patients With Hemophilia
posted April 2nd
by modernClinician Editorial Team
by modernClinician Editorial Team
Fidanacogene Elaparvovec Superior to Prophylaxis for Hemophilia B
posted September 26th
by modernClinician Editorial Team
by modernClinician Editorial Team
Editor's Recommendations
Cretostimogene Promising for High-Risk, Non-Muscle-Invasive Bladder Cancer 
Aglatimagene Besadenovec + Valacyclovir Ups DFS in Localized Prostate Cancer 
Lentiviral Gene Therapy Shows Sustained Clinical Efficacy for ADA-SCID 
Exa-Cel Gene Therapy Improves Quality of Life in Severe Sickle Cell Disease 
Efanesoctocog Alfa Prophylaxis Beneficial for Children With Hemophilia A 
ISTH Issues Clinical Practice Guideline for the Treatment of Hemophilia 
Once-Weekly Efanesoctocog Alfa Beneficial in Severe Hemophilia A 
Valoctocogene Roxaparvovec Evaluated in Severe Hemophilia A Monthly Specialist Briefings
Stay Connected
